Core Insights - Immatics N.V. has appointed Dr. Alise Reicin to its Board of Directors, bringing extensive experience in the pharmaceutical industry and a history of developing significant therapies like Keytruda® [1][2][3] - Dr. Reicin's leadership is expected to enhance Immatics' efforts in advancing TCR-based therapies for solid tumors, addressing unmet medical needs in cancer treatment [2][8] Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on discovering and developing T cell-redirecting cancer immunotherapies, with a pipeline that includes Adoptive Cell Therapies and TCR Bispecifics [4] - The company aims to enable robust T cell responses against cancer targets, leveraging partnerships with global pharmaceutical leaders [4] Leadership Experience - Dr. Reicin has held key positions in various pharmaceutical companies, including President of Global Clinical Development at Celgene and Senior Vice President at EMD Serono, contributing to the approval of multiple drugs [3] - Under her leadership at Tectonic Therapeutic, the company completed an $80 million Series A financing and advanced its first asset into clinical trials [3] Future Outlook - Dr. Reicin's appointment is set to continue through the Company's Annual General Meeting in 2025, indicating a long-term commitment to guiding Immatics' strategic direction [9] - The company is at a dynamic stage of development, particularly with its lead cell therapy candidate, ACTengine® IMA203, showing promising results in advanced metastatic melanoma patients [8]

The mean estimate comprises five short-term price targets with a standard deviation of $3.71. While the lowest estimate of $16 indicates a 27.8% increase from the current price level, the most optimistic analyst expects the stock to surge 99.7% to reach $25. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Price, Consensus and EPS Surprise While Wall Street analysts ...

Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going. Immatics (IMTX) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. However, ...

Full abstracts will be available on the ESMO website on Monday, September 9, 2024, at 00:05 CEST. Date / Time: September 16, 2024 / 11:25 CEST Session: Investigational Immunotherapy Title: Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation Presenting author: Martin Wermke, MD (University Hospital Dresden, Germany) Room: Granada Auditorium - Hall 6 IMA401 is Immatics' most advanced TCER® molecule tha ...

Memo Therapeutics AG appoints Paul Carter as Chairperson Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul will replace Elias Papatheodorou, who was instrumental in the transition of MTx from a preclinical-stage to a well-funded clinical-stage company with an ...

Immatics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $32.87 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 85.05%. This compares to year-ago revenues of $10.65 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three-month period ended March 31, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 ("Interim Financial Reporting"), as issued by the International Accounting Standards Board ("IASB"). The Consolidated Financial Statements are presented in euros. All references in this interim report to "$," and "U.S. dollars" mean U.S. dollars and all references to "€" and ...

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Houston, Texas and Tuebingen, Germany, May 14, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics"))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2024. "Our lead cell therapy candidate, IMA203, continues to show deep ...

luismmolina Investment Overview Immatics (NASDAQ:IMTX), based in Tuebingen, Germany, achieved its Nasdaq listing in 2020, via a business combination with Arya Sciences Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. According to Harvard Business Review: A SPAC is a publicly traded corporation with a two-year life span formed with the sole purpose of effecting a merger, or “combination,” with a privately held business to enable it to go public. SPACs raise ...

extended TCR Bispecifics platform. In parallel, the clinical data for our PRAME cell therapy, IMA203 GEN1, in conjunction with highly constructive FDA discussions, reinforces our confidence in advancing this asset toward a registration-enabling Phase 2/3 clinical trial in melanoma, while laying the groundwork to transition into a fully equipped commercial-stage company." Exhibit 99.1 Immatics Announces Full Year 2023 Financial Results and Corporate Update Houston, Texas and Tuebingen, Germany, March 21, 202 ...